Trans-active response DNA-binding protein of 43 kDa (TDP-43) is a highly conserved and ubiquitously expressed nuclear protein. As a member of heterogeneous ribonucleoproteins, TDP-43 plays pivotal roles in mRNA processing. We recently found that TDP-43 promoted tau mRNA instability via acting on the 3’-untranslated region of its mRNA and enhanced tau exon 10 inclusion. TDP-43 is a phospho-protein. The function and the pathological aggregation of TDP-43 are regulated by the phosphorylation. In the present study, we determined phosphorylation of TDP-43 by cyclic AMP-dependent protein kinase (PKA). We found that TDP-43 was co-immunoprecipitated by and co-localized with PKA in the nucleus. PKA phosphorylated TDP-43 at Ser379, Ser403/404, and Ser409/410 in vitro and in cultured cells. Phosphorylation of TDP-43 at these sites enhanced mutually their phosphorylation by PKA in vitro and in cultured cells. Overexpression of PKA suppressed TDP-43’s activity in promoting tau mRNA instability and tau exon 10 inclusion. These findings shed light on the role of PKA in phosphorylation and function of TDP-43. Downregulation of PKA signaling in AD brain may attenuate the impact of TDP-43 pathology in tau pathogenesis.
BurattiE, BaralleFE (2008) Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci13, 867–878.
2.
Lagier-TourenneC, PolymenidouM, ClevelandDW (2010) TDP-43 and FUS/TLS: Emerging roles in RNA processing and neurodegeneration. Hum Mol Genet19, R46–64.
3.
BoseJK, WangIF, HungL, TarnWY, ShenCK (2008) TDP-43 overexpression enhances exon 7 inclusion during the survival of motor neuron pre-mRNA splicing. J Biol Chem283, 28852–28859.
4.
HasegawaM, AraiT, NonakaT, KametaniF, YoshidaM, HashizumeY, BeachTG, BurattiE, BaralleF, MoritaM, NakanoI, OdaT, TsuchiyaK, AkiyamaH (2008) Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol64, 60–70.
5.
UryuK, Nakashima-YasudaH, FormanMS, KwongLK, ClarkCM, GrossmanM, MillerBL, KretzschmarHA, LeeVM, TrojanowskiJQ, NeumannM (2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol67, 555–564.
KogaS, KouriN, WaltonRL, EbbertMTW, JosephsKA, LitvanI, Graff-RadfordN, AhlskogJE, UittiRJ, van GerpenJA, BoeveBF, ParksA, RossOA, DicksonDW (2018) Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: A distinct clinicopathologic subtype. Acta Neuropathol136, 389–404.
8.
Grundke-IqbalI, IqbalK, QuinlanM, TungYC, ZaidiMS, WisniewskiHM (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem261, 6084–6089.
9.
HardyJ (2006) A hundred years of Alzheimer’s disease research. Neuron52, 3–13.
10.
BallatoreC, LeeVM, TrojanowskiJQ (2007) Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci8, 663–672.
11.
AndreadisA, BrownWM, KosikKS (1992) Structure and novel exons of the human tau gene. Biochemistry31, 10626–10633.
12.
GoedertM, SpillantiniMG, JakesR, RutherfordD, CrowtherRA (1989) Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron3, 519–526.
13.
IshizawaK, Ksiezak-RedingH, DaviesP, DelacourteA, TiseoP, YenSH, DicksonDW (2000) A double-labeling immunohistochemical study of tau exon 10 in Alzheimer’s disease, progressive supranuclear palsy and Pick’s disease. Acta Neuropathol100, 235–244.
14.
NeumannM, Schulz-SchaefferW, CrowtherRA, SmithMJ, SpillantiniMG, GoedertM, KretzschmarHA (2001) Pick’s disease associated with the novel Tau gene mutation K369I. Ann Neurol50, 503–513.
15.
BronnerIF, ter MeulenBC, AzmaniA, SeverijnenLA, WillemsenR, KamphorstW, RavidR, HeutinkP, van SwietenJC (2005) Hereditary Pick’s disease with the G272V tau mutation shows predominant three-repeat tau pathology. Brain128, 2645–2653.
16.
YoshidaM (2006) Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies. Neuropathology26, 457–470.
17.
Pickering-BrownS, BakerM, YenSH, LiuWK, HasegawaM, CairnsN, LantosPL, RossorM, IwatsuboT, DaviesY, AllsopD, FurlongR, OwenF, HardyJ, MannD, HuttonM (2000) Pick’s disease is associated with mutations in the tau gene. Ann Neurol48, 859–867.
18.
GuJ, WuF, XuW, ShiJ, HuW, JinN, QianW, WangX, IqbalK, GongCX, LiuF (2017) TDP-43 suppresses tau expression via promoting its mRNA instability. Nucleic Acids Res45, 6177–6193.
19.
GuJ, ChenF, IqbalK, GongCX, WangX, LiuF (2017) Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: Implications for the pathogenesis of tauopathies. J Biol Chem292, 10600–10612.
20.
SkalheggBS, TaskenK (2000) Specificity in the cAMP/PKA signaling pathway. Differential expression,regulation, and subcellular localization of subunits of PKA. Front Biosci5, D678–693.
21.
DoskelandSO, MarondeE, GjertsenBT (1993) The genetic subtypes of cAMP-dependent protein kinase–functionally different or redundant?Biochim Biophys Acta1178, 249–258.
22.
ColwillK, PawsonT, AndrewsB, PrasadJ, ManleyJL, BellJC, DuncanPI (1996) The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. EMBO J15, 265–275.
23.
KvisselAK, OrstavikS, EikvarS, BredeG, JahnsenT, CollasP, AkusjarviG, SkalheggBS (2007) Involvement of the catalytic subunit of protein kinase A and of HA95 in pre-mRNA splicing. Exp Cell Res313, 2795–2809.
24.
LiH, LiuG, YuJ, CaoW, LoboVG, XieJ (2009) In vivo selection of kinase-responsive RNA elements controlling alternative splicing. J Biol Chem284, 16191–16201.
25.
LiuF, LiangZ, ShiJ, YinD, El-AkkadE, Grundke-IqbalI, IqbalK, GongCX (2006) PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. FEBS Lett580, 6269–6274.
26.
ShiJ, QianW, YinX, IqbalK, Grundke-IqbalI, GuX, DingF, GongCX, LiuF (2011) Cyclic AMP-dependent protein kinase regulates the alternative splicing of tau exon 10: A mechanism involved in tau pathology of Alzheimer disease. J Biol Chem286, 14639–14648.
27.
GuJ, WangW, MiaoS, ChenF, WuF, HuW, IqbalK, GongCX, LiuF (2018) Protein Phosphatase 1 dephosphorylates TDP-43 and suppresses its function in tau exon 10 inclusion. FEBS Lett592, 402–410.
28.
YuQ, GuoJ, ZhouJ (2004) A minimal length between tau exon 10 and 11 is required for correct splicing of exon 10. J Neurochem90, 164–172.
InukaiY, NonakaT, AraiT, YoshidaM, HashizumeY, BeachTG, BurattiE, BaralleFE, AkiyamaH, HisanagaS, HasegawaM (2008) Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett582, 2899–2904.
35.
NeumannM, KwongLK, LeeEB, KremmerE, FlatleyA, XuY, FormanMS, TroostD, KretzschmarHA, TrojanowskiJQ, LeeVM (2009) Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol117, 137–149.
36.
KametaniF, ObiT, ShishidoT, AkatsuH, MurayamaS, SaitoY, YoshidaM, HasegawaM (2016) Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Sci Rep6, 23281.
37.
KametaniF, NonakaT, SuzukiT, AraiT, DohmaeN, AkiyamaH, HasegawaM (2009) Identification of casein kinase-1 phosphorylation sites on TDP-43. Biochem Biophys Res Commun382, 405–409.
38.
CarlomagnoY, ZhangY, DavisM, LinWL, CookC, DunmoreJ, TayW, MenkoskyK, CaoX, PetrucelliL, DetureM (2014) Casein kinase II induced polymerization of soluble TDP-43 into filaments is inhibited by heat shock proteins. PLoS One9, e90452.
39.
LiachkoNF, McMillanPJ, GuthrieCR, BirdTD, LeverenzJB, KraemerBC (2013) CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Ann Neurol74, 39–52.
40.
LiachkoNF, McMillanPJ, StrovasTJ, LoomisE, GreenupL, MurrellJR, GhettiB, RaskindMA, MontineTJ, BirdTD, LeverenzJB, KraemerBC (2014) The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43. PLoS Genet10, e1004803.
41.
ChoksiDK, RoyB, ChatterjeeS, YusuffT, BakhoumMF, SenguptaU, AmbegaokarS, KayedR, JacksonGR (2014) TDP-43 Phosphorylation by casein kinase Iepsilon promotes oligomerization and enhances toxicity in vivo. Hum Mol Genet23, 1025–1035.
42.
LiachkoNF, GuthrieCR, KraemerBC (2010) Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J Neurosci30, 16208–16219.
43.
NonakaT, SuzukiG, TanakaY, KametaniF, HiraiS, OkadoH, MiyashitaT, SaitoeM, AkiyamaH, MasaiH, HasegawaM (2016) Phosphorylation of TAR DNA-binding protein of 43 kDa (TDP-43) by truncated casein kinase 1delta triggers mislocalization and accumulation of TDP-43. J Biol Chem291, 5473–5483.
44.
AlonsoA, ZaidiT, NovakM, Grundke-IqbalI, IqbalK (2001) Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A98, 6923–6928.
45.
KosikKS, KowallNW, McKeeA (1989) Along the way to a neurofibrillary tangle: A look at the structure of tau. Ann Med21, 109–112.
46.
JosephsKA, WhitwellJL, WeigandSD, MurrayME, TosakulwongN, LiesingerAM, PetrucelliL, SenjemML, KnopmanDS, BoeveBF, IvnikRJ, SmithGE, JackCRJr, ParisiJE, PetersenRC, DicksonDW (2014) TDP-43 is a key player in the clinical features associated with Alzheimer’s disease. Acta Neuropathol127, 811–824.
47.
JosephsKA, WhitwellJL, TosakulwongN, WeigandSD, MurrayME, LiesingerAM, PetrucelliL, SenjemML, IvnikRJ, ParisiJE, PetersenRC, DicksonDW (2015) TAR DNA-binding protein 43 and pathological subtype of Alzheimer’s disease impact clinical features. Ann Neurol78, 697–709.
48.
LiangZ, LiuF, Grundke-IqbalI, IqbalK, GongCX (2007) Down-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain. J Neurochem103, 2462–2470.
49.
ShiJ, ZhangT, ZhouC, ChohanMO, GuX, WegielJ, ZhouJ, HwangYW, IqbalK, Grundke-IqbalI, GongCX, LiuF (2008) Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome. J Biol Chem283, 28660–28669.
50.
DingS, ShiJ, QianW, IqbalK, Grundke-IqbalI, GongCX, LiuF (2012) Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A. Neurobiol Aging33, 1389–1399.
